Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data
Conclusions: PIVOTAL will provide important information about the optimum dosing of IV iron in HD patients representative of usual clinical practice.Trial Registration: EudraCT number: 2013-002267-25.Am J Nephrol 2018;48:260 –268
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Cardiology | Diabetes | Dialysis | Endocrinology | Heart | Heart Attack | Heart Failure | Hemodialysis | Iron | Neurology | Stroke | Study | Urology & Nephrology